CClinicalTrials.gg
CompletedNCT05987904LP-I-CARDIAGUpdated Oct 30, 2024

Feasibility Study for Instant Cardiac Diagnostic and Post-operative Risk Assessment with the LynxPatch Device

An observational study in Cardiovascular Diseases and Heart Diseases, sponsored by Lynx Health Science GmbH. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-30.

Sponsored by Lynx Health Science GmbH · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
1,097
Ages
18 Years and older
Sex
All
01

Study summary

In this clinical study the investigators will evaluate if it is feasible to pre-operatively identify low-risk patients, and to identify patients with cardiac pathologies with the LynxPatch.

Read the detailed description

The LynxPatch is a non-invasive, wireless device for cardiac diagnosis. The aim of this study is to compare the LynxPatch predictions with the echocardiographic diagnoses of cardiac pathologies and to evaluate its perioperative risk predictions in non-cardiac surgeries. The study population includes 1100 patients that scheduled for an echocardiographic assessment or for a non-cardiac surgery. The LynxPatch measurement procedure has a duration of about 30 minutes.

02

Conditions studied

  • Cardiovascular Diseases
  • Heart Diseases

Keywords

  • Cardiac Diagnosis
03

In context

Cardiovascular Diseases

4,904 studies on the registry are indexed under Cardiovascular Diseases; 919 are open to participants now.

This study's enrollment of 1,097 is above the median of 573 across 1,485 observational studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

This is the only study on the registry with Lynx Health Science GmbH as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

In this study, all patients will be consecutively recruited that are either scheduled for an echocardiographic examination or that will be subjected to a non-cardiac surgical procedure according to their respective standard procedure.

Inclusion criteria

  • Provision of informed consent, i.e., the subject must be able to understand and sign the Patient Information and Consent Form.
  • Group 1: Patients that have an indication for an echocardiographic assessment.
  • Group 2: Patients that are scheduled for a non-cardiac surgery

Exclusion criteria

Exclusion Criteria:

  • Subjects has implanted cardioverter defibrillator
  • Subject is pregnant
  • Subject is breastfeeding
  • Subject has compromised skin in the location where the LynxPatch is intended to be positioned
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
1,097 participants (actual)
Patient registry
No

Groups and cohorts

  • Group 1: Cardiologic Group

    This group includes patients who are scheduled for echocardiography.

    Device: LynxPatch

  • Group 2: Surgery Group

    This group includes patients that are scheduled for non-cardiac surgery.

    Device: LynxPatch

Interventions

  • DeviceLynxPatch

    Measurements with the LynxPatch device are conducted.

06

What researchers measure

Primary outcomes

  1. Level of agreement between the LynxPatch device and echocardiography in detecting a cardiac pathology.

    Comparison of the detection of the presence of a cardiac pathology by the LynxPatch device and by echocardiography-based expert diagnosis.

    Time frame: 30 minutes per individual

Secondary outcomes

  1. Accuracy of the LynxPatch device predictions of an adverse perioperative outcome

    Comparison of the LynxPatch device predictions of an adverse perioperative outcome with actually occuring adverse perioperative outcome.

    Time frame: 30 days per individual

  2. Usability of the LynxPatch device

    Evaluation of aspects of the LynxPatch device's usability by interviewing study participants using a questionnaire.

    Time frame: 30 minutes per individual

  3. Rate of LynxPatch-related safety incidents

    Assessment of safety-related aspects with the LynxPatch device. Relevant incidents include Adverse Device Effects, Serious Adverse Device Effects and Device Defficiencies.

    Time frame: 30 minutes per individual

07

Study locations

1 site
  • Med. Klinik II - Kardiologie und Angiologie
    Bochum, 44789, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05987904
Lead sponsor
Lynx Health Science GmbH
Collaborators
Meditrial Europe Ltd.
Responsible party
Sponsor
First posted
Aug 14, 2023
Start date
Oct 2, 2023
Primary completion
Jun 20, 2024
Completion
Jun 20, 2024
Last update
Oct 30, 2024

Study contacts

Aydan Ewers, Dr. med.
principal investigator · BG Universitätsklinikum Bergmannsheil

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion